AU2007342005A1 - N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors - Google Patents

N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors Download PDF

Info

Publication number
AU2007342005A1
AU2007342005A1 AU2007342005A AU2007342005A AU2007342005A1 AU 2007342005 A1 AU2007342005 A1 AU 2007342005A1 AU 2007342005 A AU2007342005 A AU 2007342005A AU 2007342005 A AU2007342005 A AU 2007342005A AU 2007342005 A1 AU2007342005 A1 AU 2007342005A1
Authority
AU
Australia
Prior art keywords
optionally substituted
group
heteroaryl
heterocyclyl
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007342005A
Other languages
English (en)
Inventor
Pingyu Ding
Dane Goff
Thilo Heckrodt
Sacha Holland
Joane Litvak
Rajinder Singh
Jiaxin Yu
Jing Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of AU2007342005A1 publication Critical patent/AU2007342005A1/en
Priority to AU2014200825A priority Critical patent/AU2014200825B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2007342005A 2006-12-29 2007-12-28 N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors Abandoned AU2007342005A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014200825A AU2014200825B2 (en) 2006-12-29 2014-02-17 N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88287506P 2006-12-29 2006-12-29
US60/882,875 2006-12-29
US97544307P 2007-09-26 2007-09-26
US60/975,443 2007-09-26
PCT/US2007/089153 WO2008083354A1 (en) 2006-12-29 2007-12-28 N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014200825A Division AU2014200825B2 (en) 2006-12-29 2014-02-17 N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors

Publications (1)

Publication Number Publication Date
AU2007342005A1 true AU2007342005A1 (en) 2008-07-10

Family

ID=39203174

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007342005A Abandoned AU2007342005A1 (en) 2006-12-29 2007-12-28 N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors

Country Status (8)

Country Link
US (2) US9650391B2 (OSRAM)
EP (2) EP2074115B1 (OSRAM)
JP (2) JP5567837B2 (OSRAM)
CN (1) CN101622248B (OSRAM)
AU (1) AU2007342005A1 (OSRAM)
CA (1) CA2710046C (OSRAM)
ES (2) ES2672172T3 (OSRAM)
WO (1) WO2008083354A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884119B2 (en) * 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
CA2710230C (en) 2006-12-29 2016-02-23 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2079736B1 (en) 2006-12-29 2017-10-18 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
JP5567837B2 (ja) * 2006-12-29 2014-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用なＮ３−ヘテロアリール置換トリアゾールおよびＮ５−ヘテロアリール置換トリアゾール
WO2008083367A2 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2009054864A1 (en) * 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5711537B2 (ja) 2008-02-15 2015-05-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ピリミジン−２−アミン化合物およびｊａｋキナーゼの阻害剤としてのその使用
WO2010005879A1 (en) 2008-07-09 2010-01-14 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール
CN102281875B (zh) * 2009-01-16 2017-09-22 里格尔药品股份有限公司 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法
DK2810937T3 (en) 2012-01-31 2017-03-13 Daiichi Sankyo Co Ltd PYRIDONE DERIVATIVES
US20150164800A1 (en) 2012-07-25 2015-06-18 Xetrios Therapeutics, Inc. Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
GB201213556D0 (en) 2012-07-31 2012-09-12 Luminectric Ltd Cases for portable electronic devices
US9771333B2 (en) 2013-11-20 2017-09-26 Signalchem Lifesciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
EP3074390B1 (en) 2013-11-27 2020-07-08 SignalChem Lifesciences Corporation Aminopyridine derivatives as tam family kinase inhibitors
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
ES2896079T3 (es) 2016-02-26 2022-02-23 Ono Pharmaceutical Co Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario
JP7034084B2 (ja) 2016-03-28 2022-03-11 インサイト・コーポレイション Ｔａｍ阻害剤としてのピロロトリアジン化合物
US20200197385A1 (en) 2017-08-23 2020-06-25 Ono Pharmaceutical Co., Ltd. Therapeutic agent for cancer containing axl inhibitor as active ingredient
CA3077308A1 (en) 2017-09-27 2019-04-04 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
EA202190153A1 (ru) 2018-06-29 2021-04-09 Инсайт Корпорейшн Составы ингибитора axl/mer
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
WO2021204713A1 (en) 2020-04-08 2021-10-14 Bergenbio Asa Axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
GB202209285D0 (en) 2022-06-24 2022-08-10 Bergenbio Asa Dosage regimen for AXL inhibitor
AR129722A1 (es) 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl
WO2024051667A1 (zh) * 2022-09-05 2024-03-14 南京正大天晴制药有限公司 具有axl抑制活性的取代三唑化合物
CN121039109A (zh) * 2023-04-18 2025-11-28 国家科学研究中心 3,5-二氨基三唑衍生物及其用于治疗眼部疾病的用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1403866A (en) 1971-12-06 1975-08-28 Wyeth John & Brother Ltd Derivatives of 3-amino-1,2,4-triazoles
EP0710654A4 (en) 1993-07-23 1996-08-28 Green Cross Corp TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE
JP2002241368A (ja) 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
GB9918180D0 (en) * 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions
DE60120494T2 (de) * 2000-12-22 2006-12-21 Ortho-Mcneil Pharmaceutical, Inc. Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
DE10123586A1 (de) * 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
TW201041580A (en) 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
AU2003222310B2 (en) 2002-05-03 2009-04-09 Janssen Pharmaceutica N.V. Polymeric microemulsions
ES2378987T3 (es) 2002-08-06 2012-04-19 Toray Industries, Inc. Remedio o agente preventivo para una enfermedad renal y procedimiento para diagnosticar una enfermedad renal
WO2004039955A2 (en) 2002-10-29 2004-05-13 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
CL2003002353A1 (es) * 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
TW200514776A (en) 2003-08-06 2005-05-01 Vertex Pharma Aminotriazole compounds useful as inhibitors of protein kinases
AU2005212218A1 (en) 2004-02-11 2005-08-25 Janssen Pharmaceutica, N.V. Process for the preparation of substituted triazole compounds
DK1791830T3 (da) 2004-09-17 2011-04-18 Vertex Pharma Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
DE602005024293D1 (de) 2004-10-21 2010-12-02 Vertex Pharma Triazole als hemmer von proteinkinasen
US7884119B2 (en) 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
WO2008083367A2 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5567837B2 (ja) * 2006-12-29 2014-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用なＮ３−ヘテロアリール置換トリアゾールおよびＮ５−ヘテロアリール置換トリアゾール
EP2079736B1 (en) 2006-12-29 2017-10-18 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710230C (en) 2006-12-29 2016-02-23 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CN101778825A (zh) * 2007-03-22 2010-07-14 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的n-杂环类化合物
CN101707863A (zh) 2007-06-15 2010-05-12 Irm责任有限公司 蛋白激酶抑制剂及其使用方法
WO2009054864A1 (en) 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5711537B2 (ja) 2008-02-15 2015-05-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ピリミジン−２−アミン化合物およびｊａｋキナーゼの阻害剤としてのその使用
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール
WO2010005879A1 (en) 2008-07-09 2010-01-14 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CN102281875B (zh) 2009-01-16 2017-09-22 里格尔药品股份有限公司 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法

Also Published As

Publication number Publication date
ES2607065T3 (es) 2017-03-29
JP2014111641A (ja) 2014-06-19
CN101622248B (zh) 2013-04-17
US8796259B2 (en) 2014-08-05
EP2484679B1 (en) 2016-09-28
US20080182862A1 (en) 2008-07-31
US9650391B2 (en) 2017-05-16
EP2484679A2 (en) 2012-08-08
ES2672172T3 (es) 2018-06-12
EP2074115A1 (en) 2009-07-01
WO2008083354A1 (en) 2008-07-10
US20130090330A1 (en) 2013-04-11
JP5567837B2 (ja) 2014-08-06
CA2710046C (en) 2016-02-09
EP2074115B1 (en) 2018-03-07
CA2710046A1 (en) 2008-07-10
JP5890445B2 (ja) 2016-03-22
HK1174631A1 (en) 2013-06-14
JP2010514809A (ja) 2010-05-06
CN101622248A (zh) 2010-01-06
EP2484679A3 (en) 2012-10-10

Similar Documents

Publication Publication Date Title
EP2484679B1 (en) N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors
AU2007341937B2 (en) Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
CA2704052C (en) Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2476679B1 (en) Substituted triazoles useful as AXL inhibitors
EP2114954B1 (en) Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710230C (en) Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
JP2010514809A5 (OSRAM)
AU2014200825B2 (en) N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
AU2014200824B2 (en) Substituted triazoles useful as Axl inhibitors
HK1174631B (en) N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors
AU2016259396A1 (en) Substituted triazoles useful as Axl inhibitors
HK1132737B (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted